HDAC9 and cancer: Of the recently developed anti-cancer agents, HDAC inhibitors have been investigated in treatment of cancers, and it has been reported that several HDAC inhibitors, including suberoylanilide hydroxamic acid (SAHA), tricostatin A (TSA), valproic acid, and PCI-24781, enhance the radiosensitivities of cancer cells [10-13].